| System | Pathophysiology | Clinical Manifestation | | :--- | :--- | :--- | | | Shh deficiency → abnormal ventral patterning; cholesterol lack → poor myelination. | Microcephaly, agenesis of corpus callosum, cerebellar hypoplasia, intellectual disability, autism, self-injurious behavior. | | Craniofacial | Shh deficiency → impaired midline fusion. | Broad nasal tip, ptosis, micrognathia, cleft palate, bifid uvula. | | Limb | Aberrant Shh gradient in zone of polarizing activity (ZPA). | 2-3 toe syndactyly (pathognomonic), postaxial polydactyly, short thumbs. | | Gastrointestinal | Lack of cholesterol → smooth muscle dysmotility; Shh deficiency → abnormal gut looping. | Severe gastroesophageal reflux, pyloric stenosis, Hirschsprung disease (5-7% of cases). | | Genitourinary | Impaired androgen synthesis (cholesterol precursor for all steroids). | Hypospadias, cryptorchidism, ambiguous genitalia in 46,XY males; uterus didelphys in females. | | Skin/Adnexa | Abnormal sterol composition in keratinocyte membranes. | Photosensitivity (due to 7-DHC accumulation), dry skin, syndactyly of toes. |
Smith-Lemli-Opitz syndrome (SLOS) is an autosomal recessive, multiple congenital anomaly syndrome that was first described by American pediatricians David W. Smith, Luc Lemli, and John M. Opitz in 1964. It is now recognized as one of the most common inborn errors of cholesterol metabolism. The disorder is characterized by a classic triad of microcephaly, distinctive facial features, and syndactyly of the second and third toes, alongside a wide spectrum of visceral, neurological, and growth abnormalities. Fisiopatologia De Smith Thier
Understanding the pathophysiology of SLOS requires a deep dive into the mevalonate-cholesterol biosynthesis pathway and the pleiotropic effects of cholesterol deficiency during embryogenesis and postnatal development. | System | Pathophysiology | Clinical Manifestation |